Abstract: SA-PO0465
Utilization Rates of SGLT2 Inhibitors, RAS Inhibition, GLP-1 Receptor Agonists, and Finerenone in Patients with CKD (eGFR = 30-89 mL/min/1.73 m2) and Type 2 Diabetes
Session Information
- CKM: Clinical - Screening, Population Management, Care Disparities, and Patient-Centered Outcomes
October 24, 2026 | Location: Exhibit Hall A, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Cardiovascular-Kidney-Metabolic Health
- 602 Cardiovascular-Kidney-Metabolic Health: Clinical
Authors
- Santos, James Urbano, Stony Brook Medicine, Stony Brook, New York, United States
- Bano, Ruqiyya, Stony Brook Medicine, Stony Brook, New York, United States
- Mallipattu, Sandeep K., Stony Brook Medicine, Stony Brook, New York, United States
Background
Type 2 diabetes is a leading cause of chronic kidney disease (CKD) and accelerates its progression. Despite several therapies that lower kidney and cardiovascular risks, their real-world use remains unclear. This study examined trends in kidney-protective therapy use in diabetic CKD over 10 years with TrinetX.
Methods
We conducted a retrospective cohort study using TriNetX de-identified EHR data from Stony Brook University Hospital and global networks (US, APAC, LATAM, EMEA) from 2016–2025. We evaluated temporal and geographic trends in SGLT2 inhibitor, RAS inhibitor, GLP-1, and finerenone use based on guideline indications.
Results
The prevalence of CKD increased globally: APAC rose from 25.1% to 29.9%, EMEA from 23.8% to 28.3%, LATAM from 13.6% to 20.9%, and the USA from 24.9% to 27.3%. RAS inhibitors were most used (41%-79%), while SGLT2 inhibitors (up to 36%) and GLP-1 agonists (1%-19%) were underutilized. Finerenone use was low (0-3%).
From 2016–2025, RAS inhibitor use in SBU stayed at 77-79%. SGLT2 inhibitor use rose from 3.8% to 24.2%, GLP-1 agonist use from 5.4% to 18.8%, and finerenone reached 0.56% by 2025.
Year-over-year, SGLT2 inhibitor grew by 45% at SBU and 38% in the USA. GLP-1 agonist use rose from 12% to 18%, peaked at 22% in 2022, and dipped to 15% in 2020. RAS inhibitor use was stable (1-2%); finerenone rose but stayed below 5%.
Conclusion
Cases of CKD with type 2 diabetes has increased from 2011 to 2025. While RAS inhibitors are most used, SGLT2 inhibitor and GLP-1 agonist adoption has risen. Finerenone remains underutilized, revealing the need for targeted interventions.